Prothena (PRTA) AI Stock Analysis

• Market Cap: $573.29M
• Dividend Yield: N/A
• Average Volume (3M): 732.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -95.24%
• EPS Growth: -493.05%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 53,829,930
• 10 Day Avg. Volume: 686,318
• 30 Day Avg. Volume: 732,465
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.06
• Enterprise Value/Revenue: -3.38
• Enterprise Value/Gross Profit: -3.70
• Enterprise Value/Ebitda: 0.14
• 1Y Price Target: $16.50
• Price Target Upside: 54.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 53 Neutral
• Price Target: $10.50 ▼(-1.41% Downside)

Prothena's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and negative profit margins. Despite these challenges, the stock shows positive technical momentum, which provides some optimism. However, the negative P/E ratio and lack of dividend yield weigh down the valuation score, reflecting ongoing profitability issues.

Positive Factors

Strategic Partnerships

Prothena's partnership with Bristol Myers Squibb, including potential milestone payments, enhances its financial prospects and supports long-term growth.

Regulatory Progress

The Fast Track Designation for BMS-986446 accelerates its development, potentially leading to faster market entry and revenue generation for Prothena.

Pipeline Advancement

Advancing coramitug into Phase 3 with Novo Nordisk signifies progress in Prothena's pipeline, indicating potential future revenue streams and market impact.

Negative Factors

Declining Revenue

Significant revenue decline poses a challenge to Prothena's financial stability and may hinder its ability to fund ongoing R&D and operational activities.

Negative Profit Margins

Sustained negative profit margins indicate ongoing profitability challenges, potentially impacting Prothena's ability to invest in growth and innovation.

Cash Flow Challenges

Negative cash flows highlight liquidity issues, limiting Prothena's financial flexibility and potentially affecting its long-term operational capabilities.

Prothena Business Overview & Revenue Model

Company Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

How the Company Makes Money

Prothena generates revenue through a combination of collaborations, licensing agreements, and potential milestone payments from its partnerships with pharmaceutical companies. The company enters into strategic alliances with larger biopharmaceutical firms that provide upfront payments and ongoing funding to support the development of its drug candidates. Additionally, Prothena may receive royalties on product sales if its partnered therapies reach the market. The company also has the potential for milestone payments as its candidates progress through various stages of clinical development, thereby contributing significantly to its earnings.

Prothena Financial Statement Overview

Summary

Prothena shows revenue growth, but persistent losses and cash burn are significant concerns. The company maintains a strong equity position and cash reserves, yet ongoing negative profitability metrics and cash flow issues present risks. Improving profitability is essential for long-term sustainability.

Income Statement

Prothena's revenue has shown growth over the years, with a notable increase from 2020 to 2025. However, the company is currently operating at a loss as evidenced by negative EBIT and net income. Gross profit margin is positive, indicating some operational efficiency, but the net profit margin is negative, highlighting ongoing profitability challenges.

Balance Sheet

The company's balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, leading to a favorable debt-to-equity ratio. The equity ratio is high, indicating financial stability. However, the return on equity is negative due to persistent net losses, which is a concern for investors.

Cash Flow

Prothena's cash flow situation is challenging with negative operating and free cash flow, suggesting cash burn. The operating cash flow to net income ratio is negative due to ongoing losses, but the company has maintained a decent cash reserve, which provides some buffer.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.34M	135.16M	91.37M	53.91M	200.58M	853.00K
Gross Profit	9.43M	135.16M	-129.20M	47.16M	118.29M	-74.03M
EBITDA	-248.10M	-154.56M	-190.11M	-131.56M	71.97M	-111.22M
Net Income	-302.92M	-122.31M	-147.03M	-116.95M	66.97M	-111.14M
Balance Sheet
Total Assets	399.07M	547.11M	696.38M	758.03M	609.37M	332.98M
Cash, Cash Equivalents and Short-Term Investments	371.44M	471.39M	618.83M	710.41M	579.09M	295.38M
Total Debt	9.78M	10.84M	11.84M	6.47M	12.33M	17.84M
Total Liabilities	74.73M	60.18M	135.02M	135.99M	143.32M	148.97M
Stockholders Equity	324.33M	486.93M	561.37M	622.04M	466.04M	184.01M
Cash Flow
Free Cash Flow	-196.69M	-150.35M	-136.72M	-109.28M	92.03M	-80.56M
Operating Cash Flow	-196.74M	-150.05M	-133.91M	-108.82M	92.61M	-80.36M
Investing Cash Flow	-184.94K	-298.00K	-2.77M	-464.00K	-575.00K	-196.00K
Financing Cash Flow	147.29K	1.55M	45.10M	241.46M	190.33M	215.00K

Prothena Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTA, the sentiment is Positive. The current price of 10.65 is above the 20-day moving average (MA) of 10.17, above the 50-day MA of 9.22, and above the 200-day MA of 9.62, indicating a bullish trend. The MACD of 0.33 indicates Positive momentum. The RSI at 63.36 is Neutral, neither overbought nor oversold. The STOCH value of 51.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTA.

Prothena Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LXRX	―	$483.32M	-3.99	-65.30%	―	1504.83%	56.81%
ZVRA	―	$568.09M	-186.03	3.53%	―	158.57%	96.76%
PRTA	―	$573.29M	-1.89	-66.85%	―	-95.24%	-493.05%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XOMA	―	$420.53M	-22.55	-12.42%	―	194.98%	38.01%
ALMS	―	$490.14M	―	-66.35%	―	―	-25.20%
CRVS	―	$572.27M	―	-68.67%	―	―	-50.83%

Prothena Corporate Events

Prothena Announces Promising Phase 1 Results for PRX012

On August 27, 2025, Prothena announced results from its Phase 1 ASCENT clinical program for the investigational drug PRX012, aimed at treating early symptomatic Alzheimer’s disease. The study demonstrated that PRX012, a once-monthly, subcutaneous anti-amyloid beta antibody, showed promising results in reducing amyloid plaque but had higher ARIA-E rates compared to FDA-approved antibodies. Prothena plans to seek partnerships to further develop PRX012 and its preclinical PRX012-TfR antibody, which may offer a reduced risk of ARIA and quicker amyloid plaque reduction.

The most recent analyst rating on (PRTA) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.

Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk

On August 6, 2025, Prothena announced that its partner Novo Nordisk will advance coramitug, a potential first-in-class amyloid depleter antibody, into Phase 3 development for ATTR amyloidosis with cardiomyopathy. This decision follows the successful completion of a Phase 2 trial and is expected to commence in 2025. Prothena stands to earn a clinical milestone payment upon meeting specific enrollment criteria in the Phase 3 trial. The advancement of coramitug marks a significant step in addressing the unmet needs of patients with ATTR amyloidosis, potentially enhancing Prothena’s industry positioning and offering substantial financial benefits through its agreement with Novo Nordisk.

The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.

Prothena Reports Q2 2025 Financial Results and Pipeline Progress

Prothena Corporation plc is a biotechnology company specializing in the development of therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. In its latest earnings report, Prothena highlighted significant advancements in its pipeline, including the progression of prasinezumab into Phase 3 trials for Parkinson’s disease and the upcoming release of initial data from the Phase 1 ASCENT clinical trials for Alzheimer’s treatment PRX012. Financially, Prothena reported a net loss of $125.8 million for the second quarter of 2025, attributed to restructuring charges and a non-cash income tax expense, with total revenue significantly lower than the previous year due to reduced collaboration revenue. The company maintains a strong cash position of $372.3 million, with expectations to end the year with approximately $298 million. Looking ahead, Prothena plans to convene an Extraordinary General Meeting by year-end to propose a share capital reduction, potentially enabling a share redemption program, while continuing to advance its clinical programs and collaborations.

Prothena Secures Leadership with New Executive Agreements

On July 30, 2025, Prothena Biosciences Inc entered into employment agreements with key executives, including the Chief Strategy Officer, Chief Operating Officer, and Chief Scientific Officer. These agreements outline their base salaries, bonus opportunities, and severance benefits, which align with the company’s existing severance plan. The agreements provide for enhanced severance benefits in the event of termination without cause or resignation for good reason, with further increases if such termination occurs in connection with a change in control. This move is likely to impact the company’s operations by securing leadership stability and potentially positioning the company more favorably in the industry.

The most recent analyst rating on (PRTA) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.